Morgan Stanley analyst Emmet Kelly resumed coverage of Cellnex with an Equal Weight rating and EUR 44 price target. The company’s organic growth story is underappreciated, but its step back from expansionary acquisitions removes an opportunity to "turbo-charge" its bottom line, Kelly tells investors in a research note.
Meet Samuel – Your Personal Investing Prophet
- Start a conversation with TipRanks’ trusted, data-backed investment intelligence
- Ask Samuel about stocks, your portfolio, or the market and get instant, personalized insights in seconds
Published first on TheFly